UBA6 and melanoma: To directly evaluate the relationship between UBA6 expression and ICB responses, we analysed the clinical dataset in a melanoma cohort treated with anti-CTLA445 and observed that UBA6 expression was negatively predictive of the progression-free survival of ICB-treated patients (Fig. 6b).